Needham raised the firm’s price target on GH Research (GHRS) to $29 from $19 and keeps a Buy rating on the shares. The price target increase reflects a higher probability of success for GH001 following the announcement of IND clearance on Monday, the analyst tells investors in a research note. GH001 demonstrated impressive efficacy in Phase 2 vs. competition at Day 2/Day 8 and a potentially game-changing 73% remission rate at 6 months with re-treatments, Needham says.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- GH Research price target raised to $39 from $35 at Canaccord
- Midday Fly By: U.S. oil majors rise on Venezuela news, Versant completes spinoff
- GH Research: Pivotal Pathway for GH001 in Treatment-Resistant Depression Supports $35 Target and Reiterated Buy Rating
- GH Research Wins FDA Clearance to Advance GH001 for Treatment-Resistant Depression
- GH Research: FDA Lifts Clinical Hold on GH001, Clearing Path to Phase 3 and Supporting Buy Rating